title: Measurement of serum calprotectin in stable patients predicts exacerbation and lung function decline in cystic fibrosis.
authors.affiliation: 1 Western General Hospital Edinburgh, Scotland.
authors.forename: Philip A
authors.initials: PA
authors.lastname: Reid
authors.forename: David A
authors.initials: DA
authors.lastname: McAllister
authors.forename: A Christopher
authors.initials: AC
authors.lastname: Boyd
authors.forename: J Alastair
authors.initials: JA
authors.lastname: Innes
authors.forename: David
authors.initials: D
authors.lastname: Porteous
authors.forename: Andrew P
authors.initials: AP
authors.lastname: Greening
authors.forename: Robert D
authors.initials: RD
authors.lastname: Gray
mesh_terms: D000328:Adult; D015415:Biomarkers / Q000097:blood; D003550:Cystic Fibrosis / Q000097:blood*; D018450:Disease Progression; D005541:Forced Expiratory Volume; D006801:Humans; D039841:Leukocyte L1 Antigen Complex / Q000097:blood*; D008168:Lung / Q000503:physiopathology*; D008297:Male; D011379:Prognosis; D016016:Proportional Hazards Models; D011446:Prospective Studies; D013997:Time Factors; D014797:Vital Capacity
chemical_list: D015415:Biomarkers; D039841:Leukocyte L1 Antigen Complex